Summary
Intrahepatic cholestasis of pregnancy (ICP) requires the earliest possible treatment, as it increases the risk of premature delivery and fetal distress. Furthermore, the severity of pruritus in ICP may interfere with the mother’s well-being. We present results of a trial involving an additional 55 cases of ICP (mean age 29 years), who received SAMe 800 mg/day intravenously at the onset of ICP, for 10 to 30 days. Clinical assessment of pruritus and measurements of serum total bile salts (STBS), serum total and conjugated bilirubin (STB, SCB), serum alkaline phosphatase (SAP), and aspartate and alanine aminotransferases (AST, ALT) were performed before and after therapy. SAMe treatment significantly (p < 0.01) decreased STBS (18.3 ± 3.4 vs 23.1 ± 3.4 μmol/L), SCB (7.8 ± 0.8 vs 10.7 ± 1.2 μmol/L), SAP (4.7 ± 0.2 vs 6.1 ± 0.3 μkat/L), AST (0.9 ± 0.1 vs 2.0 ± 0.2 μkat/L), and ALT (1.6 ± 0.1 vs 2.9 ± 0.2 μkat/L) levels compared with basal values. At baseline, most patients exhibited normal STB and therefore no significant change in this parameter was recorded after therapy. Pruritus was significantly improved after SAMe treatment, and was reduced in 15 patients and had disappeared in 40 patients. No adverse reactions were observed. There were no cases of premature labour, and all newborns had normal Apgar scores (mean 8.2) and were of normal weight for gestational age. These results further support the use of SAMe therapy in ICP.
Similar content being viewed by others
References
Arias IM. Mechanisms and consequences of ion transport in the liver. In Popper M & Schaffner F (Eds) Progress in liver diseases. Vol. 8, pp. 145–159, Grune & Stratton, New York, 1986
Bell KM, Plon L, Bunney WE, Potkin SG. S-adenosylmethionine treatment of depression: a controlled clinical trial. American Journal of Psychiatry 145: 1110–1114, 1988
Bergasa NV, Jones A. Management of the pruritus of cholestasis: potential role of opiate antagonists. American Journal of Gastroenterology 86: 659–670, 1991
Boelsterli UA, Rakhit G, Balazs T. Modulation by S-adenosyl-L-methionine of hepatic Na+, K+-ATPase, membrane fluidity, and bile flow in rats with ethynylestradiol-induced cholestasis. Hepatology 3: 12–17, 1983
Bonfirraro G, Chieffi O, Quinti R, et al. S-Adenosyl-L-methionine (SAMe)-induced amelioration of intrahepatic cholestasis of pregnancy. Results of an open study. Drug Investigation 2: 125–128, 1990
Boyer JL. Treatment of intrahepatic cholestasis. In Rodés J, Arroyo V (Eds) Therapy in liver diseases, pp. 73–82, Ediciones Doyma, Barcelona, 1991
Chawla RK, Bonkovsky HL, Galambos JT. Biochemistry and pharmacology of S-adenosyl-L-methionine and rationale for its use in liver disease. Drugs 40: 98–110, 1990
Combes B, Shore GM, Cunningham FG, et al. Serum γ-gluta-myltranspeptidase activity in viral hepatitis: suppression in pregnancy and by birth control pills. Gastroenterology 72: 271–274, 1977
Espinoza J, Barnafi L, Schnaidt E. The effect of phenobarbital on intrahepatic cholestasis of pregnancy. American Journal of Obstetrics and Gynecology 119: 234–238, 1974
Frezza M, Centini G, Cammareri G, Le Grazie C, Di Padova C. S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy: results of a controlled clinical trial. He-pato-Gastroenterology 37: 122–125, 1990
Frezza M, Di Padova C. Multicenter placebo controlled clinical trial of intravenous and oral S-adenosyl-L-methionine (SAMe) in cholestatic patients with liver disease. Abstract. Hepatology 7: 1105, 1987a
Frezza M, Pozzato G, Chiesa L, Stramentinoli G, Di Padova C. Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine administration. Hepatology 4: 274–278, 1984
Frezza M, Pozzato G, Pison G, et al. S-adenosylmethionine counteracts oral contraceptive hepatotoxicity in women. American Journal of the Medical Sciences 30: 234–238, 1987b
Fricker G, Landmann L, Meier PJ. Ethinylestradiol (EE)-induced structural and functional alterations of rat liver plasma membranes and their reversal by S-adenosylmethionine (SAMe) in vitro. Abstract. Hepatology 8: 1224, 1988
Ghent CN. Pruritus of cholestasis is related to effects of bile salts on the liver, not the skin. American Journal of Medicine 82: 117–118, 1987
Heikkinen J. Serum bile acids in the early diagnosis of intrahepatic cholestasis of pregnancy. Obstetrics and Gynecology 61: 581–587, 1983
Hirata F, Axelrod J. Phospholipid methylation and biochemical signal transmission. Science 209: 1082–1090, 1980
Johnston WG, Basken TF. Obstetric cholestasis: a 14-year review. American Journal of Obstetrics and Gynecology 133: 299–301, 1979
Kagan BL, Sultzer D, Rosenlight N, Gerner RH. Oral S-adenosyl-L-methionine in depression: a double-blind, placebo-controlled trial. American Journal of Psychiatry 447: 591–595, 1990
Kreek MJ. Female sex steroids and cholestasis. Seminars in Liver Diseases 7: 8–23, 1987
Laatikainen T. Effect of cholestyramine and phenobarbital on pruritus and serum bile acid levels in cholestasis of pregnancy. American Journal of Obstetrics and Gynecology 132: 501–506, 1978
Lafuenti G, Plotti G, Nicolanti G, et al. Valutazione delie modificazioni di parametri clinici e biochimici in gravide con colestasi in terapia con S-adenosyl-L-methionine per os. Giornale Italiano di Ostetricia e Ginecologia 10: 357–361, 1988
Larrauri A, Castell JV, Garrido G, Berenguer J, Gomez-Lechon MJ. S-adenosyl-L-methionine reverses ethynylestradiol-induced impairment on taurocholate uptake in primary cultures of rat hepatocytes. Abstract. Gastroenterology 96: 520, 1989
Lunzer M, Barnes P, Byth K, et al. Serum bile acid concentrations during pregnancy and their relationship to obstetric cholestasis. Gastroenterology 91: 825–829, 1986
Ostrow JD. Therapeutic amelioration of jaundice: old and new strategies. Hepatology 8: 683–689, 1988
Reid R, Ivey KJ, Rencoret RH, Storey B. Fetal complications of obstetric cholestasis. British Medical Journal 1: 870–872, 1976
Reyes H. The enigma of intrahepatic cholestasis of pregnancy: lessons from Chile. Hepatology 2: 87–96, 1982
Reyes H, Radrigan ME, Gonzalez MC, et al. Steatorrhea in patients with intrahepatic cholestasis of pregnancy. Gastroenterology 93: 584–590, 1987
Ribalta J, Reyes H, Gonzalez MC, et al. S-Adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology 13: 1084–1089, 1991
Schorr-Lesnick B, Lebovics E, Dworkin B, Rosenthal WS. Liver diseases unique to pregnancy. American Journal of Medicine 86: 659–670, 1991
Schreiber AJ, Simon FR. Estrogen-induced cholestasis: clues to pathogenesis and treatment. Hepatology 3: 607–613, 1983
Schreiber AJ, Warren G, Sutherland E, Simon FR. S-adenosyl-methionine (SAMe)-induced cytoprotection against bile acid-induced cholestasis. Abstract. Gastroenterology 84: 1395, 1983
Steven MM. Pregnancy and liver disease. Gurt 22: 592–614, 1981
Stramentinoli G, Di Padova C, Gualano M, Rovagnati P, Galli-Kienle M. Ethynylestradiol-induced impairment of bile secretion in the rat: protective effects of S-adenosyl-L-methionine and its implications in estrogen metabolism. Gastroenterology 80: 154–158, 1981
Vendemiale G, Altomare E, Trizio T, et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scandinavian Journal of Gastroenterology 24: 407–415, 1989
Vore M. Estrogen cholestasis: membranes, metabolites, or receptors?. Gastroenterology 93: 643–649, 1986
Young DS. Implementation of SI units for clinical laboratory data. Annals of Internal Medicine 106: 114–129, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Catalino, F., Scarponi, S., Cesa, F. et al. Efficacy and Safety of Intravenous S-Adenosyl-L-Methionine Therapy in the Management of Intrahepatic Cholestasis of Pregnancy. Drug Invest 4 (Suppl 4), 78–82 (1992). https://doi.org/10.1007/BF03258367
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03258367